Kornimate/medical-research-clean huggingface dataset:
comparison of low-dose, standard-dose ticagrelor and clopidogrel for inhibition of platelet reactivity in patients with acute coronary syndromes

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to compare low-dose, standard-dose ticagrelor and clopidogrel for inhibition of platelet reactivity in patients with acute coronary syndromes


Eligibility criteria:
inclusion criteria: * st elevation or non st elevation acute coronary syndrome patients of chest pain within 24 hours exclusion criteria: * known hypersensitivity to clopidogrel and ticagrelor and aspirin * treatment with anticoagulants * exposure to a thrombolytic agent within 24 hours prior to randomization * use of glycoprotein iib - iiia inhibitors at randomization * history of major hemorrhage (intracranial, gastrointestinal, etc.) * clotting disorder and/or bleeding disorder * any history of severe renal or hepatic dysfunction * hematologic disorder including a hemoglobin less than 10 g/l or a platelet count less than 80,000 cells/mm3 * cardiac shock, severe left ventricular dysfunction lvef less than 30% * sick sinus syndrome or second degree of av block without permanent pacemaker * no concurrent cytochrome p450 3a inhibitors and enhancers within 2 weeks * subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg,drug and alcohol abuse, mental illness) or that could prevent, limit, or confound the protocol-specified assessments. * life expectancy of less than 6 months * pregnancy or lactating * participation in any drug study in the previous 3 months * inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk

Keywords: inhibition of platelet reactivity ticagrelor clopidogrel pharmacodynamics pharmacokinetics
a study for the treatment of unresectable stage iii or metastatic stage iv melanoma

Conditions: Melanoma

Summary: a study with ym155 for the treatment of unresectable stage iii or metastatic stage iv melanoma.

a phase ii, multicenter, open-label study in subjects with unresectable stage iii or metastatic (stage iv) melanoma to evaluate the efficacy and safety of ym155

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed unresectable stage iii or iv malignant melanoma * life expectancy \>12 weeks exclusion criteria: * history of other malignancy in the last 5 years * major surgery within the past 21 days

Keywords: treatment efficacy treatment effectiveness disease management treatment safety malignant melanoma
this is a phase 1 study to evaluate the safety,tolerability and virology of ct p59 in patients with mild symptoms of symptoms of coronavirus disease (covid-19)

Conditions: SARS-CoV-2 Infection

Summary: this is a phase i study that randomized, double-blind, placebo-controlled, parallel group, single ascending dose study to evaluate safety, tolerability and virology of ct-p59 in patient with mild symptoms of severe acute respiratory syndrome coronavirus (sars-cov-2) infection.

'ct-p59 is a monoclonal antibody targeted against sars-cov-2 spike receptor binding protein as a treatment for sars cov 2 infection. ct-p59 is currently being developed by the sponsor as a potential treatment for sars-cov-2 infection. in this study, safety, tolerability and virology of ct-p59 will be evaluated in patient with mild symptoms of sars-cov-2 infection.

Eligibility criteria:
inclusion criteria: each patient must meet all of the following criteria to be randomized in this study: 1. adult male or female patient, aged between 18 to 60 years (both inclusive). 2. patient with laboratory confirmed sars-cov-2 infection by reverse transcription polymerase chain reaction (rt-pcr) at screening. 3. patient has mild conditions meeting all of the following criteria: 1. oxygen saturation ≥ 94% on room air. 2. not requiring supplemental oxygen. 4. onset of symptom is no more than 7 days prior to the study drug administration. exclusion criteria: 1. patient with severe condition meeting one of the following: 1. respiratory distress with respiratory rate ≥ 30 breaths/min. 2. requires supplemental oxygen. 3. experience shock. 4. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. 5. any other conditions suspected of being severe symptoms of sars-cov-2 infection, in the opinion of the investigator, including but not limited to radiographic findings in lung.
povidone iodine irrıgation at hip-knee arthroplasty

Conditions: Osteoarthritis; Hyperthyroidism; Iodine Toxicity

Summary: povidone iodine (pi) solution is an antimicrobial solution that can be used at hip and knee arthroplasty cases. it contains iodine that may be absorbed by the body. this study aims to investigate any absorption caused by pi solution.


Eligibility criteria:
inclusion criteria: * all patients with hip/knee osteoarthritis who undergo primary arthroplasty exclusion criteria: * patients with abnormal thyroid function tests in the preoperative period, a history of the previous thyroid-related disease.
study of the correlation between ultrasonography and dual-energy computed tomography assessment of urate deposit

Conditions: Gout

Summary: the objective of this research is to evaluate the correlation between dect and us explorations performed in a routine clinical setting for the measurement of change in tophus size in gout patients after 24 months of treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of gout based on the acr/eular 2015 criteria * uricemia ≥6 mg/dl * warranted introduction of urate-lowering therapy according to the acr 2012 or eular 2016 criteria * signature of the informed consent * social insurance affiliation exclusion criteria: * pregnancy or breastfeeding * patient under legal guardianship

Keywords: dual-energy computed tomography ultrasonography gout urate deposition
medium dose of cytarabine and mitoxantrone

Conditions: Acute Myelogenous Leukemia; Chemotherapy

Summary: by observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on aml-high dose of cytarabine and ham.

the patients of aml in shenzhen people's hospital were randomly divided into two therapy groups.one group was treated by high dose of cytarabine ,and the other was ham.evaluate the two chemotherapy schemes by bone marrow suppression time and patient survival time.

Eligibility criteria:
inclusion criteria: people diagnosed as aml exclusion criteria: * acute promyeloytic leukemia

Keywords: aml ham
brief intervention combined with health coaching via social media for cannabis use

Conditions: Cannabis Use

Summary: the purpose of the study is to develop and test social media interventions to help young people increase well-being and reduce risky behaviors. the study will help researchers learn about ways to deliver wellness information in a way that is appealing and helpful to young people who use snapchat.


Eligibility criteria:
inclusion criteria: individuals seen in the emergency department at hurley medical center who meet these criteria * self-report of weekly or more frequent cannabis use for past 3 months * past month snapchat use * ability to consent * english-speaking * between ages 18-25 * smart phone ownership exclusion criteria: * emergency department presentation for suicidality and/or acute psychosis, being in police custody, or present with psychological distress requiring intensive social work (e.g. sexual assault) * having a medical cannabis card
single adductor-canal-block versus peri-articular infiltration on outcome after total knee arthroplasty

Conditions: Osteoarthritis,Knee

Summary: the purpose of this study is to compare the effect of single adductor-canal-block versus single femoral nerve block on the recovery after total knee arthroplasty.

the aim of this study is to assess the effect of different analgesic effects on the outcome of patients undergoing total knee arthroplasty. patients who will have primary unilateral total knee replacement between september 2016 to june 2018 at peking union medical college hospital and meet the inclusion criteria will be included. they are randomized into two groups. the total knee arthroplasty is performed by one surgeon and adductor-canal block is performed by one anesthesiologist who is not responsible for follow-up. patients on both groups will have intravenous patient control analgesia with 1 mg morphine/bolus. one residency is responsible for the follow-up.

Eligibility criteria:
inclusion criteria: * osteoarthritis * unilateral total knee arthroplasty * asa grade i - ii * normal cognitive function. exclusion criteria: * patients refuse * bmi \> 35 * diagnosis other than osteoarthritis * allergy to the drugs used or contraindication to the intervention

Keywords: knee arthroplasty adductor canal block periarticular infiltration
consequences in icu of vaccination status of covid-19 patients

Conditions: SARS CoV 2 Infection

Summary: it is a retrospective cohort study aiming to describe the characteristics, management and prognosis of vaccinated patients hospitalized in the intensive care unit (icu), in comparison with non-vaccinated patients.

in december 2019 started the first wave of sars-cov-2 virus infections in wuhan, china : the start of a major, deadly global pandemic, which has so far caused more than 6 million deaths worldwide. in response to the scale of this pandemic, a large-scale vaccination campaign was rapidly in place, starting in december 2020. despite this measure, admission of vaccinated patients to intensive care has been noticed. the aim of this study is to describe the characteristics, management and prognosis of vaccinated patients hospitalized in the intensive care unit (icu), in comparison with non-vaccinated patients.

Eligibility criteria:
inclusion criteria: * adult patient with sars-cov-2 pneumonia confirmed by positive reverse transcription polymerase chain reaction (rt-pcr) assay and hospitalized in the general intensive care unit of the chr de metz-thionville, between 01/03/2020 and 01/06/2022. exclusion criteria: * missing data for primary or secondary outcomes
left atrial appendage closure in combination with catheter ablation

Conditions: Atrial Fibrillation

Summary: this study is a prospective cohort study aimed at investigating the efficacy and safety of left atrial appendage closure in combination with catheter ablation in patients with atrial fibrillation.

this study is a prospective cohort investigating the efficacy and safety of catheter ablation in combination with left atrial appendage closure in patients with atrial fibrillation. this study will be conducted in accordance with the following procedures: 1. screen out patients in accordance with the inclusion and exclusion criteria. the following assessments should be made: demographic data, medical history, physical examination, vital signs data, the height and body weight, laboratory parameters, ecg examination, assessment for medication and evaluation for inclusion/exclusion criteria. 2. participants receive radiofrequency ablation in combination with left atrial appendage closure. participants will be assessed and observed carefully during and after the operation. 3. the participants will be followed-up in the third, ninth and twelfth months after the treatments. the main follow-up includes the review of ecg, 24h holter monitoring, echocardiography, transesophageal echocardiography, coronary ct et al. and afeqt questionnaire, and brain ct or mri if necessary. participants' medication and symptoms will also be observed and recorded. the incidence of stroke, systemic embolism, transient ischemic attack, major bleeding and all-cause death; the rate of patients maintaining sinus rhythm, hospitalization due to heart failure, and perioperative complications such as pericardial tamponade, wound hematoma and long-term surgery-related complications will be recorded. adverse events during the trial will also be assessed and recorded.

Eligibility criteria:
inclusion criteria: 1. history of paroxysmal/persistent/longstanding persistent atrial fibrillation 2. refractory to at least one antiarrhythmic drug or unwilling to receive long-term antiarrhythmic drugs; 3. with contraindication of longterm anticoagulation or unwilling to receive longterm anticoagulation 4. cha2ds2-vasc score ≥ 2 and/or has-bled score ≥ 3 5. provide informed consent to participate in the study; 6. between 18-90 years exclusion criteria: 1. myocardial infarction within 3 months 2. stroke or systemic embolism within 3 months 3. plan to receive heart transplantation; 4. life expectancy less than 1 year; 5. severe bleeding diseases that cannot be treated with short-term anticoagulants; 6. with left atrial or left atrial appendage thrombus; 7. with uncontrolled malignant tumor ; 8. obvious liver and kidney dysfunction (alt, ast more than 2 times the upper limit of normal, or ccr \<50%); 9. women who are pregnant, or breastfeeding. 10. other conditions not suitable to the combined procedure.
gallbladder stenting in fc-sems

Conditions: Biliary Obstruction; Acute Cholecystitis

Summary: the goal of this randomized controlled trial is to determine whether primary prophylaxis with transpapillary gallbladder drainage prevents acute cholecystitis after fully-covered self-expandable metal stents placement during endoscopic retrograde cholangiopancreatography for malignant distal biliary obstruction in patients at higher risk of post-endoscopic retrograde cholangiopancreatography acute cholecystitis. the main question it aims to answer is: does prophylactic transpapillary gallbladder drainage reduce the rate of post-endoscopic retrograde cholangiopancreatography acute cholecystitis in high-risk patients? researchers will compare patients who undergo transpapillary gallbladder drainage to patients without transpapillary gallbladder drainage to see if transpapillary gallbladder drainage reduces the rate of acute cholecystitis. participants will: 1. receive or not transpapillary gallbladder drainage before fully-covered self-expandable metal stents placement 2. will be followed up at one, three, and six months to ascertain the onset of acute cholecystitis


Eligibility criteria:
inclusion criteria: * adult patients * signed informed consent * patients requiring covered metal stent placement for managing mbo * high-risk of post-endoscopic cholangiopancreatography acute cholecystitis according to the following criteria: * tumor involvement of the cystic duct orifice confirmed on magnetic resonance imaging, computed tomography, endoscopic ultrasound, or at endoscopic cholangiopancreatography; * presence of at least 2 of the following: 1. gallbladder stones; 2. cbd diameter ≤ 10 mm; 3. intraprocedural gallbladder opacification; 4. cystic duct orifice at risk of being covered by the fully-covered stent exclusion criteria: * history of cholecystectomy * endoscopic retrograde cholangiopancreatography not feasible for duodenal stenosis or failed biliary cannulation * patients with previous gallbladder drainage * acute cholecystitis is already present based on the tokyo guidelines
neurofeedback treatment of pain in persons with spinal cord injury (sci)

Conditions: Spinal Cord Injuries; Pain

Summary: a number of studies suggest that training to increase different types of brain waves is related to pain relief. the purpose of the second phase of this study is to see if neurofeedback training might help people with chronic pain control their pain better. the information from the study may help the investigators treat chronic pain better in the future.

during this phase of the study, research personnel will provide up to 15 of the subjects with sci-related pain with a full course (up to 40 sessions) of nf training to determine the effects of this treatment on (a) chronic daily pain, (b) eeg-assessed frequency band amplitudes, and (c) other measures of quality of life (specifically, sleep quality, fatigue, and pain interference). standard nf training procedures will be used that involve simply asking participants to relax while looking at the feedback screen and to "do whatever is necessary to make and keep the color bar wide." eeg bandwidth activity that is associated with being pain-free or with experiencing less pain will be reinforced. this protocol will be repeated for up to 40 30-minute sessions, scheduled at least weekly (but more often if the participant and study pi can arrange this with their schedules. brain wave activity will be measured three times during the study: once before treatment begins, once immediately after treatment ends, and three months following treatment. research staff will collect data regarding pain intensity and quality of life from subjects via the telephone three times: before treatment, immediately after treatment, and three months after treatment ends.

Eligibility criteria:
inclusion criteria: 1. 18 years old or older. 2. at least 12 months post-sci. 3. otherwise healthy (i.e., no other secondary medical complications, such as pressure ulcers, that could impact pain scores). 4. read, write and understand english. 5. experience sci-related pain on a daily basis. 6. report an average pain intensity of at least 4 on a 0-10 numerical scale. 7. an individual must have one significant pain problem that is the worst or most painful if he/she has more than one pain problem. 8. pain problem has lasted at least six months, and began after injury. exclusion criteria: 1. history of seizure activity or has non-normative brain activity. 2. suicidal or paranoid thoughts. 3. presence of traumatic brain injury or significant skull defects.

Keywords: neurofeedback
influence of z shaped and conventional sulcular incisions on healing and interproximal bone loss in implant surgery

Conditions: Bone Loss; Healing Surgical Wounds

Summary: the present study is a human, prospective, parallel, randomised controlled clinical trial conducted to check the interproximal bone loss of z shaped incision over conventional sulcular h shaped incision.the trial is in accordance with the consolidated standards of reporting trials (consort) criteria, 2010.

twenty healthy individuals satisfying the inclusion and exclusion criteria were recruited for the study. a detailed, thorough medical and dental history was obtained and each patient was subjected to comprehensive clinical and radiological examination. all patients were informed about the nature of the study, the surgical procedure involved, potential benefits and risks associated with the surgical procedure and written informed consent were obtained from all patients. in the test group patients z shaped incision was done to place implants and h shaped sulcular incision was placed in control group. the clinical and radiographic parameters were recorded at baseline,24 hours,7days, three months and six months postoperatively.

Eligibility criteria:
inclusion criteria: 1. patients with single or multiple edentulous spaces in the maxillary and mandibular arches having siebert's class 1 and 2 ridge defects. 2. patients willing to participate in the study. 3. patients above 18 years of age. 4. patients exhibiting keratinized tissue width more than or equal to 2 mm. 5. systemically healthy patients. 6. patients who demonstrate full mouth plaque control and bleeding scores\<25% and showing good compliance. exclusion criteria: 1. patients who do not give consent. 2. untreated periodontal disease, caries. 3. insufficient oral hygiene. 4. smokers. 5. previous radiation therapy. 6. patients with known systemic diseases and conditions 7. pregnant and lactating women.

Keywords: implant incisions bone loss z shaped incision
pleural and pericardial effusion following open heart surgery

Conditions: Heart Disease; Pleural Effusion; Pericardial Effusion

Summary: one of the most common postoperative complications after open cardiac surgery is fluid accumulation between the pleural membranes or in the pericardial sac. this study investigates the consequence of such fluid accumulations on physical performance, recovery-time, cardiac and respiratory complications, and quality of life. half of the participants will be followed closely and offered fluid drainage at a low threshold, and half of the participants will follow the current postoperative regimen.

introduction: knowledge concerning the impact of pleural and pericardial effusions on physical performance, recovery-time, cardiac and respiratory complications, and quality of life after open cardiac surgery is scarce. a more aggressive approach towards effusions has been suggested, but further studies are needed. objectives: 1. to determine the size of pleural and pericardial effusion that results in at least 30% reduction of physical performance in the 6-minute walk test. 2. to compare the improvement in physical performance between the intervention group and the control group, measured from baseline to day 30 after surgery. materials and methods: a randomised controlled intervention trial. patients admitted for open cardiac surgery (aortic valve surgery, coronary artery bypass graft surgery and combinations) will be randomised into either an intervention group or a control group. the intervention group will be followed with physical tests and ultrasonic examination the month following surgery. pleural or pericardial effusion of a predefined size will be drained. the control group will follow the current postoperative regimen.

Eligibility criteria:
inclusion criteria: * age \>18 years. * admitted for elective aortic valve surgery, coronary artery bypass graft surgery or combinations. * be able to understand the written and oral patient information and to give informed consent. exclusion criteria: * surgical combinations involving the mitral valve since they are already examined with full echocardiography prior to discharge, which may influence protocol driven decisions. * simultaneous participation in any other clinical intervention trial

Keywords: cardiac surgery postoperative treatment pleural effusion physical performance
effect of angeliq on blood pressure (bp) in postmenopausal hypertensive women

Conditions: Hypertension; Postmenopause

Summary: the objective of the study is to evaluate the effects of angeliq on bp over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (hrt) for the relief of vasomotor symptoms and who have hypertension.

this study has previously been posted by berlex, inc. berlex, inc. has been renamed to bayer healthcare pharmaceuticals, inc.bayer healthcare pharmaceuticals, inc.is the sponsor of the trial.

Eligibility criteria:
inclusion criteria:- have hypertension- are currently taking antihypertensive medications- have had natural menopause at least 1 year prior to screening- must require hormone therapy in the opinion of the investigator

Keywords: postmenopausal vasomotor symptoms essential hypertension